2-[3-Cyano-4-(2-Methylpropoxy)Phenyl]-4-Methyl-1,3-Thiazole-5-Carboxylic Acid

Acquisition and downstream processing of 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid typically adhere to monographic specifications for febuxostat as the sole intended pharmacologically active moiety. Commercial consignments exhibiting a purity of 99.7% (area normalization, HPLC at 230 nm) or greater are qualified directly for solid oral dosage form manufacture without an intermediate recrystallisation step, provided residual solvent limits specified under USP 〈467〉 Procedure A and elemental impurity thresholds per ICH Q3D are satisfied. Bulk powder handling characteristics — notably the high electrostatic charge propensity of particles with a volume-median diameter (Dv50) consistently below 15 µm — dictate downstream processing strategy. Unmilled material typically exhibits a Dv50 between 25 µm and 40 µm, a poured bulk density near 0.28 g/cm³, and a Hausner ratio exceeding 1.45, indicating cohesiveness that complicates gravity-fed tablet press tooling. The compound is sparingly soluble in aqueous media across physiological pH, with equilibrium solubility measured at 37 °C in pH 6.8 phosphate buffer reported below 12 µg/mL, placing it solidly in BCS Class II territory and making particle size control the primary lever for achieving bioequivalent performance.

Direct-Compression Tablet Manufacturing: Blend Uniformity at Low Potency

Formulators supplying regulated markets in North America and under EU Mutual Recognition frequently adopt a direct-compression platform containing 8.3 wt% to 10.7 wt% of the active compound, equivalent to the 80 mg or 120 mg label-claim strengths per unit dose. A representative diluent matrix developed from production-scale batches run on a 16-station rotary press (Korsch XL 100 or equivalent) combines spray-dried lactose monohydrate (NF, Ph.Eur.) at 68–72 wt%, microcrystalline cellulose (Avicel PH-102) at 16–20 wt%, and croscarmellose sodium at 2.5–3.5 wt% as a intra- and extra-granular superdisintegrant. Colloidal silicon dioxide is split-introduced: 0.5 wt% premixed with the active compound during a manual geometric dilution step to coat particle surfaces and suppress agglomerate persistence, and a further 0.3 wt% added to the final blend as a flow-aid. Magnesium stearate (vegetable-source, specific surface area 4–8 m²/g) is sieved through a 60-mesh screen and tumble-blended for a duration not exceeding 5 minutes at 25 rpm in a bin blender; blend times beyond 8 minutes have been linked to delayed dissolution profiles under USP 〈711〉 Apparatus 2 (paddle, 50 rpm, 900 mL pH 6.8 buffer) due to hydrophobic filming of lubricant onto newly cleaved fracture surfaces created during particle fragmentation. Content uniformity testing per USP 〈905〉 on stratified samples drawn from the discharged bin routinely yields acceptance values below 4.2, provided the blend is transferred to the press hopper via a split-butterfly valve system that minimizes vertical segregation. Tablet compression is executed to a target hardness of 8–12 kp (diameter 9.0 mm, round, standard concave), monitored with an automatic weight control feedback loop; ejection force above 220 N signals insufficient die-wall lubrication and triggers an in-process magnesium stearate level adjustment within the pre-blend. Terminal de-dusting and metal-checking precede a non-functional film-coating step using an Opadry II aqueous dispersion at 3.0–4.0% weight gain, with pan inlet air temperature held at 65 ± 5 °C and atomization air pressure at 2.0 bar. The finished product is released against a shelf-life specification that includes dissolution stage S1/S2 criteria of Q = 80% at 30 minutes, individual highest impurity (2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxamide) ≤ 0.15%, and total impurities ≤ 0.5%, all determined by a validated gradient HPLC method with UV detection at 315 nm.

When the active pharmaceutical ingredient is ordered against a CEP (Certificate of Suitability to the European Pharmacopoeia) and accompanied by a stability protocol conducted per ICH Q1A(R2) under climatic zone IVb conditions (30 °C/75% RH), downstream tablet production can proceed with re-test dating anchored to the least stable physical attribute. The main operational boundary encountered on production lines is the narrow particle-size specification window: over-micronisation producing a Dv10 below 2 µm increases unpaired surface hydroxyl density on fractured crystal faces, which elevates the water sorption rate at RH > 60% to a point where progressive hydrolysis of the nitrile group becomes detectable via HPLC within 24 hours. For this reason, primary packaging in Alu-Alu cold-form blister cavities sealed with a desiccant-loaded lidding foil is standard for climate zone IV shipments, and humidity exposure during the capsule banding or tablet film-coating phases is stringently capped at 45% RH with real-time dew-point monitoring of inlet air.

Is Wet-Granulation Technology Justifiable for a Brittle, Fracture-Prone Active?

While direct compression is overwhelmingly preferred due to the compound’s sensitivity to moisture and thermal stress, a minority of manufacturers elect a high-shear wet-granulation route when a single-pot processor is already qualified on site and cannot accommodate the segregation risk of a low-dose dry blend. Granulation fluid is prepared as a 5.0% w/w aqueous solution of pregelatinised starch (Starch 1500), sprayed at a rate of 45–60 g/min onto a pre-blend containing 8.7 wt% active compound, 75 wt% lactose monohydrate (grade 200 mesh), 10 wt% microcrystalline cellulose (grade 101), and 1.3 wt% crospovidone (type B). Impeller speed is maintained at 200 ± 20 rpm and chopper at 1500 rpm; end-point is determined by power consumption inflection on a load cell equipped Gral processor, corresponding to a median granule size (geometric mean diameter) near 180–220 µm. After wet massing, the material is discharged onto a fluid-bed dryer (Glatt GPCG) and dried at an inlet temperature of 55 °C until a loss-on-drying value between 1.5% and 2.0% is achieved, measured by halogen moisture balance at 105 °C. Exceeding 60 °C inlet temperature during this step has been shown to generate a detectable increase in the carboxamide degradant, presumably through the acid-catalysed hydration of the nitrile group fostered by the slightly acidic microclimate of wet granulation; published data for this specific configuration is limited, but in-line NIR monitoring of the cyano-band (ca. 2230 cm⁻¹) is recommended as a process analytical technology to close the feedback loop. The dried granules are milled through a conical screen (Quadro Comil, round impeller, 0.050-inch screen) and lubricated in the same manner as the direct-compression process, with the additional requirement that residual moisture homogeneity across sublots is confirmed by Karl Fischer titration (USP 〈921〉, Method Ia) before compression. Oxygen-impermeable packaging is mandatory for any granulated intermediate held longer than 72 hours because the increased surface area accelerates radical-mediated oxidation of the thiazole ring, detectable via a yellowing of the granule bed that precedes measurable purity loss by approximately 48 hours under ambient storage.

Reference-listed drug (RLD) dissolution curves filed with the FDA under ANDA 202-116 establish the expected discriminatory power of the paddle method, and any lot failing to surpass 80% at 30 min in QC release testing is cross-checked against the RLD in multimedia (pH 1.2, 4.5, 6.8) with an f2 acceptance threshold of 50. It is critical to recognise that the compound’s solubility profile exhibits a steep pH-dependency: solubility at pH 1.2 (HCl medium) is less than 1.5 µg/mL, creating a rate-limiting dissolution bottleneck in the gastric environment that renders the selection of superdisintegrant type and grade disproportionately influential. Crospovidone-containing formulations consistently demonstrate shorter disintegration times (below 3 minutes in 900 mL water at 37 °C, basket-rack apparatus per USP 〈701〉) relative to sodium starch glycolate, and this parameter directly anticorrelates with inter-lot dissolution variability observed during commercial-scale production campaigns exceeding 300 kg batch size.

Manufacturing sites operating under a Site Master File with EU competent authorities often anchor their process validation to a bracketed approach covering the 80 mg and 120 mg dose strengths, on the principle that blend uniformity risk is maximised at the lower dose. A minimum blend potency RSD of 3.5% (n = 30) at the press hopper outlet, verified by stratified sampling across three consecutive batches, constitutes the primary acceptance criterion before filing a Process Performance Qualification protocol. Statistical process control charts for tablet weight, hardness, and disintegration are maintained per ICH Q10 and ICH Q8(R2) design-space expectations, with alert limits at ±2σ and action limits at ±3σ derived from 25 historical batches. No lot is released into the supply chain without passing 100% visual inspection and automated weight sorting on a check-weighing system capable of rejecting individual tablets at a rate exceeding 200,000 units per hour.

Micronised APIs and Inhalation-Grade Particle Engineering

Although not indicated for pulmonary delivery, a niche but growing application involves preparing research-grade micronised lots for intratracheal administration in preclinical rodent models of hyperuricemia, where the compound serves as a reference inhibitor against emerging xanthine oxidase candidates. Fluid energy milling (jet milling) using a Pancaked Loop mill (Sturtevant qualification mill, 2-inch diameter) with a feed rate of 80–120 g/hour and a grinding pressure of 6.9 bar, followed by a single-pass Venturi classification, yields a Dv90 consistently below 7.0 µm and a Dv50 between 2.5 µm and 3.5 µm as measured by laser diffraction dry dispersion (Malvern Mastersizer 3000, 2.0 bar dispersion pressure). The steep input curve of this milling set-up necessitates continuous micro-feeder verification with a loss-in-weight gravimetric controller; excursions above 150 g/hour result in a bimodal particle size distribution with a coarse tail above 20 µm that invalidates the lot for aerosolisation studies. Electrostatic charge accumulation on freshly fractured surfaces is mitigated by conditioning the micronised powder in a nitrogen-flushed glove bag at 40–45% RH for 6 hours prior to aliquoting, and all subsequent handling employs type 316L stainless steel contact surfaces that have been electro-polished to a surface finish of Ra 0.8 µm or better. The particulate is aliquoted into amber Type I glass vials under ISO Class 5 laminar flow, stoppered with teflon-faced butyl closures, and tested against a research-specification certificate that includes endotoxin levels (LAL test per USP 〈85〉) below 0.25 EU/mg and a visible particle count compliant with USP 〈790〉 (essentially free of visible foreign matter). Researchers combining the micronised powder with a lactose carrier (typically Lactohale LH200) for dry-powder insufflator administration adhere to a 1:99 active-to-carrier weight ratio, established by in-vitro cascade impactor studies (Next Generation Impactor, 60 L/min, 4 L air volume) that achieve a fine particle fraction (≤5 µm) in excess of 55% of loaded dose. The limitation that must be respected is the compound’s propensity to form hygroscopic bridges with α-lactose monohydrate at RH ≥ 50%, a phenomenon that shifts the mass median aerodynamic diameter upwards by approximately 1.5 µm within 48 hours of ambient storage; thus, ternary-blend inclusion of 0.5% hydrophobic fumed silica (Aerosil R972) is sufficient to extend blend homogeneity through a 24-hour dosing cycle.

Preparing Calibrator and Quality-Control Stock Solutions Under ISO 17025 Governance

Analytical laboratories characterising febuxostat impurity profiles utilise the pure compound as a primary calibrator for HPLC-UV and UPLC-MS/MS platforms, provided the batch holds a current certificate of analysis that assigns a mass-balance purity factor determined under a strict orthogonal protocol: HPLC area% at 230 nm and 315 nm, water content (Karl Fischer coulometric, 10 mg sample, Hydranal Coulomat AG), residual solvents by headspace GC-FID with G43 column, and residue on ignition (USP 〈281〉, 1.0 g, 800 °C). Only lots with mass-balance purity 99.5% or above and a defined total uncertainty of measurement (k = 2, confidence level 95%) below 0.6% are accepted for CRM (certified reference material) candidacy. Stock solutions are customarily prepared at a concentration of 1.0 mg/mL in methanol (HPLC grade) with sonication for 10 minutes at 30 °C; a precision assessment across 6 independent weighings must yield an RSD below 0.5% before the solution is aliquoted and sealed under argon headspace for long-term storage at -20 °C. These stock solutions remain stable for 24 months when perfluoroelastomer septa are used, as evidenced by sequential LC-TOF monitoring that confirms no detectable formation of the primary hydrolytic degradant (acid form of the amide) at a limit of quantification of 0.02 µg/mL. Linearity studies spanning 0.1 µg/mL to 200 µg/mL (r² ≥ 0.9995) anchor the calibration range for substances determined in raw material and tablet matrices. The unique operational risk in an ISO 17025 environment arises from the chemical’s photo-isomerization under UV-A radiation: solutions exposed to laboratory lighting for more than 8 cumulative hours, even when in amber volumetric flasks, show a systematic bias of +0.15% in the assigned purity value due to co-elution of a trace Z-isomer, which is separable only on a pentafluorophenylpropyl (F5) column with an isocratic mobile phase of acetonitrile/0.1% formic acid (45:55 v/v). Accordingly, light-protective amber vials in combination with secondary aluminium foil wraps, and a written procedure limiting bench-top cumulative light exposure to 3 hours, are enforced.

In the context of dissolution testing cross-validation, the compound is employed directly as the reference standard at a working concentration of 0.0088 mg/mL (equivalent to 100% release of an 80 mg tablet in 900 mL medium) in pH 6.8 buffer. The dissolution medium preparation protocol stipulates pre-heating to 37 °C ± 0.5 °C with deaeration by helium sparging at a flow rate sufficient to reduce dissolved oxygen below 2.0 ppm, as dissolved oxygen above 5.0 ppm induces a slow oxidative decarboxylation that depresses the apparent recovery of the standard by 1.0–1.8% over the 24-hour benchtop stability window used in automated dissolution autosamplers. Laboratories that have adopted the USP Performance Verification Test (PVT) criteria for paddle apparatus suitability routinely include a pre-dose assessment of the standard solution’s absorbance against an NIST-traceable potassium dichromate solution to flag solvent degradation, and any shift in lambda max exceeding 2 nm triggers medium re-preparation.

Compounding into Preclinical Transdermal and Oral Suspension Formulations

Contract research organisations supporting in vivo pharmacokinetic and toxicokinetic studies formulate the compound into 0.5% w/v suspension vehicles for oral gavage to Sprague-Dawley rats and beagle dogs. The vehicle vehicle most consistently yielding dose-proportional exposure in GLP 14-day bridging studies consists of 0.5% carboxymethylcellulose sodium (medium viscosity, 1500–3000 cP, 2% solution), 0.1% polysorbate 80 (NF), and 0.9% benzyl alcohol as preservative in sterile water for injection, adjusted to a final pH of 6.0–6.5 with 1N NaOH. The active compound is wetted with polysorbate 80 before trituration in a glass mortar, then gradually incorporated into the CMC gel while stirring under overhead agitation at 500 rpm for 30 minutes to ensure macroscopic homogeneity. Particle size analysis of the final suspension must demonstrate a Dv90 ≤ 15 µm to prevent needle clogging in 18-gauge gavage tips; re-agitation via magnetic stirring is required immediately and continuously during automated dosing sessions because settling rates exceed 2.0 cm/hour in the CMC matrix. Dosing-acceptance criteria specified in an institutional animal care and use committee (IACUC) protocol typically cap the AUC0-t variation coefficient at 25% across 8 animals per group, a target that becomes unattainable if the suspension is prepared more than 6 hours in advance without cold-chain storage (2–8 °C), as aggregation of needle-shaped primary crystals evolves into a false-dose distribution. There is a notable formulation incompatibility with polyethylene glycol 400-based vehicles: the carboxyl group of the compound forms ester adducts with PEG-400 in a pH- and temperature-dependent reaction that can consume up to 4.5% of the active content within 48 hours at 25 °C, so PEG-containing excipients are strictly excluded from any suspension in which the compound is to be dissolved or partially dissolved rather than purely suspended. For transdermal flux measurement studies using Franz diffusion cells, a simple 1.0% w/w carbomer gel (Carbopol 980, neutralised to pH 6.0 with triethanolamine) is loaded with 2.0% w/w of the micronised powder (Dv50 3.5 µm) and cast to a 500-µm wet film thickness on a shaved Sprague-Dawley rat skin membrane. The permeation profile under occluded conditions yields a lag time of 8–12 hours and a steady-state flux of 0.12–0.25 µg/cm²/h, which is deemed insufficient for therapeutic transdermal delivery but adequate for local tissue distribution assays; attempts to raise flux above 0.5 µg/cm²/h by adding oleic acid (5.0%) as a permeation enhancer result in dissolution of the crystalline depot in the gel and a paradoxical decline in cumulative permeation beyond 24 hours due to vehicle-scavenging effects, an outcome consistent with the compound’s BCS Class II behaviour where solubilisation in the vehicle retards thermodynamic activity.

Process development reports from facilities that have scaled the compound to 300 kg batch sizes highlight a critical dependence on excipient source variability: microcrystalline cellulose from different manufacturers exhibits statistically significant differences in the angle of internal friction (measured by Schulze ring shear tester, pre-shear 5 kPa), which directly impacts tablet weight variability under high-speed compression exceeding 80,000 tablets per hour. Switching from an Asian-sourced to a European-sourced grade of lactose monohydrate (both meeting Ph.Eur. specifications) required re-optimisation of the magnesium stearate mixing protocol because the mean particle size of the lactose shifted from 170 µm to 210 µm, expanding the blend’s bulk volume by 7% and altering the effective shear rate during lubrication. Such adjustments must be recorded in the site change-control system under ICH Q7 and be accompanied by a supplementary bioequivalence bridging report when the reference product is the subject of an approved ANDA. Throughout all stages of handling, the explicit incompatibility of the compound with primary or secondary amine-based excipients — including chitosan, polyethyleneimine, and basic butylated methacrylate copolymers (Eudragit E) — derives from the formation of an ion-pair complex via the carboxylic acid moiety, resulting in a significant depression of the compound’s pKa from 3.3 to an apparent value below 1.8 in the matrix, which completely arrests dissolution in any medium with a pH above 4.0. This incompatibility is confirmed by observing a persistent tablet core remaining intact well beyond 120 minutes in dissolution vessels, a hallmark of carboxyl-amine adduct gelling at the solid-liquid interface. No combination of the compound with these polymers should be pursued without prior solid-state ¹³C MAS NMR screening to verify an absence of carboxylate anion shifting, and even then, long-term stability under ICH conditions is rarely assured.